Lorenzo Braghieri, Douglas L Jennings, Bruno Bohn, Marlena Habal, Alberto Pinsino, Giulio M Mondellini, Annamaria Ladanyi, Farhana Latif, Kevin Clerkin, Susan Restaino, Paul Kurlansky, Koji Takeda, Yoshifumi Naka, Ryan T Demmer, Gabriel T Sayer, Nir Uriel, Paolo C Colombo, Melana Yuzefpolskaya
STUDY OBJECTIVE: Mycophenolate mofetil (MMF) is the gold-standard immunosuppressive agent in heart transplantation (HT), but dose-dependent toxicities (e.g., neutropenia) are frequent. Gut bacteria β-d-glucuronidases (GUS) modulate MMF bioavailability, and changes in the intestinal flora may influence the pharmacokinetics of MMF. The objective of this study was to evaluate the safety and efficacy of MMF 1.5 g every 12 h (q12) [high-dose, HD] versus 1 g q12 [low-dose, LD] and explore the association between neutropenia and GUS...
September 2022: Pharmacotherapy